The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
60 Degrees Pharmaceuticals Pretax Margin % Related Terms
60 Degrees Pharmaceuticals Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SXTP vs GLMD, FBLG, CELZ: Pretax Margin % Comparison
For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
60 Degrees Pharmaceuticals Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where 60 Degrees Pharmaceuticals's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
60 Degrees Pharmaceuticals (SXTP) has a Pretax Margin % of -1,290.12% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on 60 Degrees Pharmaceuticals and its competitors. According to the industry distribution chart, 60 Degrees Pharmaceuticals ranks #708 out of 942 companies in the Biotechnology industry, placing it in the top 75.2%.
Is 60 Degrees Pharmaceuticals' Pretax Margin % too high?
60 Degrees Pharmaceuticals' current Pretax Margin % is -1,290.12%. Based on the distribution chart, 60 Degrees Pharmaceuticals ranks #708 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, 60 Degrees Pharmaceuticals has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 60 Degrees Pharmaceuticals' Pretax Margin % compare to GLMD and FBLG?
According to the Biotechnology industry distribution chart, 60 Degrees Pharmaceuticals ranks #708 out of 942 companies for Pretax Margin %. This places 60 Degrees Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on 60 Degrees Pharmaceuticals and its competitors. 60 Degrees Pharmaceuticals's current Pretax Margin % is -1,290.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 60 Degrees Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals (SXTP) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.05, compared to a current price of $1.75 — trading 14.6% below its estimated fair value. The current Pretax Margin % is -1,290.12%. 60 Degrees Pharmaceuticals' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For 60 Degrees Pharmaceuticals (SXTP), the current Pretax Margin % is -1,290.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 60 Degrees Pharmaceuticals (SXTP) Overvalued in 2026?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals stock appears to be undervalued.
The current stock price of $1.75 is trading 14.6% below its estimated GF Value™ of $2.05.
GuruFocus considers 60 Degrees Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for SXTP:
Pretax Margin %: -1,290.12%
GF Value™: $2.05 vs. price of $1.75 (14.6% below fair value)
No single metric tells the full story. See the SXTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
44GF Score
Get the complete analysis for SXTP
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SXTP has been successfully added to your 
